Skip to main content

Table 2 Base case results representing an annual cohort from England (primary outcomes)

From: A model-based assessment of the cost–utility of strategies to identify Lynch syndrome in early-onset colorectal cancer patients

Strategy

1(2)

2

3

4

5

6

7

8

Incremental costs vs Strategy 1(1) [£ Thousands]

Diagnosis

48.9

662.7

578.5

599.6

586.0

636.9

1061.6

1336.6

CRC prevention

396.7

735.9

726.9

822.1

817.1

817.1

928.8

1065.7

CRC treatment

−249.3

−646.9

−646.2

−725.5

−725.2

−725.2

−814.0

−848.8

EC prevention

210.4

338.1

333.2

377.3

374.5

374.5

427.0

499.6

EC treatment

−21.7

−60.6

−60.6

−68.0

−68.0

−68.0

−76.2

−78.7

Total

384.9

1029.2

931.8

1005.4

984.5

1035.3

1527.1

1974.5

Incremental QALYs vs Strategy 1(1)

Short-term

0

−4.3

−4.1

−4.8

−4.6

−4.6

−5.5

−8.5

Long-term

63.9

164.0

163.9

184.0

183.9

183.9

206.4

214.8

Total

63.9

159.7

159.8

179.2

179.3

179.3

200.9

206.3

Cost–utility

ICER vs Strategy 1(1) [cost per QALY gained]

£6021

£6444

£5831

£5610

£5491

£5774

£7601

£9571

ICER [cost per QALY gained]

ED

D

ED

D

£5491

D

£25106

£82962

INHB at WTP £20000/QALY vs 1(1) [QALYs]

44.7

108.3

113.2

129.0

130.1

127.5

124.5

107.6

  1. Key: D, dominated; EC, endometrial cancer; ED, extended dominated; WTP, willingness-to-pay.